Breaking Finance News

Zacks Investment Research downgraded Galectin Therapeutics Inc (NASDAQ:GALT) to Hold in a report released today.

Yesterday Galectin Therapeutics Inc (NASDAQ:GALT) traded 1.11% higher at $0.82. The company’s 50-day moving average is $0.83 and its 200-day moving average is $1.43. The last stock close price is down -37.27% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 725,769

Zacks Investment Research has downgraded Galectin Therapeutics Inc (NASDAQ:GALT) to Hold in a report released on Tuesday November 29, 2016.

Previously on 11/28/2016, Zacks Investment Research reported about Galectin Therapeutics Inc (NASDAQ:GALT) raised the target price from $0.00 to $1.00. At the time, this indicated a possible upside of 0.10%.

See Chart Below

Galectin Therapeutics Inc (NASDAQ:GALT)

Galectin Therapeutics Inc has a 52 week low of $0.49 and a 52 week high of $3.05 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 3 firms have reported on the stock. The consensus target price is $8.33 with 1 firm rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Galectin Therapeutics Inc (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *